Biolife Solutions INC: directors' dealings · United States · SEC (Form 4)

About Biolife Solutions INC

BioLife Solutions Inc. is a U.S.-based company listed on the Nasdaq under the ticker BLFS in the United States. The company focuses on bioproduction tools and services for the cell and gene therapy (CGT) industry, with an emphasis on protecting cell integrity, improving manufacturing reproducibility, and reducing risk across storage, transport, and processing workflows. In practical terms, BioLife sells specialized products used by biopharma customers to preserve the viability of sensitive biological material through critical steps in the CGT supply chain. Its current messaging and filings consistently describe the company as a developer and supplier of cell processing tools and services for the CGT market.([biolifesolutions.com](https://www.biolifesolutions.com/?utm_source=openai)) BioLife has a long operating history and evolved over time from a more narrowly focused preservation-products company into a broader bioproduction platform serving advanced therapies. The company is headquartered in Bothell, Washington, where it also maintains manufacturing, R&D, marketing, and administrative functions. That footprint gives BioLife a strong operational base in the U.S. biotech corridor while serving a customer base that extends well beyond the domestic market.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026012294/blfs-20251231.htm?utm_source=openai)) Its core business lines include biopreservation media, cell-culture optimization products, closed-system filling and storage solutions, and related shipping and handling technologies. Well-known product families include CryoStor and HypoThermosol, alongside complementary solutions aimed at preserving cell quality, lowering contamination exposure, and supporting aseptic manufacturing. The strategic appeal of BioLife lies in the fact that it is not competing as a broad pharma manufacturer; instead, it occupies a specialized enabling layer in the CGT ecosystem, where process reliability and regulatory validation matter more than scale alone.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/a2025blfsinvestorpresent.htm?utm_source=openai)) From a competitive standpoint, BioLife appears well positioned as a niche leader. Its products are embedded in demanding CGT workflows, and investor materials indicate meaningful traction across clinical trials and approved therapies. That kind of embedded usage can create sticky customer relationships, higher switching costs, and a defensible role in an industry where manufacturing complexity remains a major bottleneck. The company’s market position is therefore best understood as a high-value infrastructure supplier to the advanced-therapy value chain rather than a conventional life-sciences vendor.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026013277/a2025blfsinvestorpresent.htm?utm_source=openai)) Recent developments have reinforced the strategic shift toward higher-quality revenue and profitability. BioLife reported full-year 2025 results on February 26, 2026, followed by first-quarter 2026 results on May 7, 2026. The company also issued 2026 guidance and continued to highlight growth in its core CGT franchise. For investors following insider activity and SEC Form 4 filings, BLFS combines an innovation-driven business model, exposure to the long-term CGT theme, and a Nasdaq listing in the United States with a more focused, margin-oriented portfolio after recent portfolio adjustments.([sec.gov](https://www.sec.gov/Archives/edgar/data/834365/000162828026012264/blfsq42025earningsrelease.htm?utm_source=openai))